Die Chemische und Pharmazeutische Industrie ist nicht zuletzt wegen ihrer starken Export- und Forschungsorientierung einer der Wachstumsträger der deutschen Volkswirtschaft. Prinzipiell gilt dies auch für Ostdeutschland. Wie in diesem Beitrag gezeigt wird, sind insbesondere die dortigen...

This paper quantifies the relationship between market size and innovation in the pharmaceutical industry. We estimate the elasticity of innovation, as measured by the number of new chemical entities appearing on the market for a given disease class, to the potential market size represented by...

This paper studies oligopolistic competition in off-patent pharmaceutical markets using a vertical product differentiation model. This model can explain the observation that countries with stronger regulations have smaller generic market shares. It can also explain the differences in observed...

This paper examines how equitable, differentiated pricing can improve access to and affordability of medicines, particularly in low- and middle-income countries, and how governments and supranational agencies can create an environment that enables pharmaceutical companies to operate a...

The Indian pharmaceutical industry is presently going through a phase of transition and potential consolidation, owing to India's new TRIPS-compliant intellectual property regime and other rules aimed at enhancing the industry's credibility nationally and internationally. Appropriate policy...

This study shows that R&D cooperation can be used as an instrument to coordinate drug development portfolios among participating firms, which has crucial implications on the number of drugs offered on the market. Our study puts special attention to the fact that R&D cooperation, formed at...

Introduction: In 2009, the Swedish pharmaceuticals market was reformed. One of the stated policy goals was to achieve low costs for pharmaceutical products dispensed in Sweden. Methods: Prices and sales data for off-patent brand-name and generic pharmaceuticals have been collected, and a...

The paper focuses on some organizational dynamics that have characterized pharmaceutical industry in the last thirty years, when biotechnology and the development of life sciences have defined a new technological paradigm, reshaping many aspects of the industry, especially the organization of...

We study size and growth distributions of products and business firms in the context of a given industry. Firm size growth is analyzed in terms of two basic mechanisms, i.e. the increase of the number of new elementary business units and their size growth. We find a power-law relationship...